GSK2636771

Base Information

• Chemical Name: GSK2636771
• CAS No.: 1372540-25-4
• Molecular Formula: C22H22F3N3O3
• Molecular Weight: 433.43
• Mol file: 1372540-25-4.mol

Synonyms:UNII-DW94IAT0LS;CS-0747;2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid;QCR-187;

Chemical Property of GSK2636771

Chemical Property:

• Boiling Point: 641.3±55.0 °C(Predicted)
• PKA: -2.70±0.30(Predicted)
• PSA: 67.59000
• Density: 1.38
• LogP: 4.32000
• Storage Temp.: -20°C Freezer
• Solubility.: DMSO (Slightly), Methanol (Slightly)

Purity/Quality:

98%,99%, ^*data from raw suppliers

GSK2636771 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Uses: GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Technology Process of GSK2636771

There total 6 articles about GSK2636771 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 88.0%

methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate (1372540-24-3) → 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid (1372540-25-4)

Guidance literature:

methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate; With water; lithium hydroxide; In tetrahydrofuran; at 50 ℃; for 1h;

pH=3; Acidic conditions;

Reference yield:

5-chloro-2-nitrobenzoic acid (2516-95-2) → 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid (1372540-25-4)

Guidance literature:

Multi-step reaction with 6 steps

1.1: potassium tert-butylate; N-methoxylamine hydrochloride / copper diacetate / N,N-dimethyl-formamide / 3 h / 0 °C / Inert atmosphere

1.2: pH 1

2.1: triethylamine; HATU / tetrahydrofuran / 3 h / 20 °C

3.1: potassium carbonate / N,N-dimethyl-formamide / 5 h / 110 °C

4.1: iron / 5 h / Reflux

5.1: potassium carbonate / N,N-dimethyl-formamide / 3 h / 80 °C

6.1: water; lithium hydroxide / tetrahydrofuran / 1 h / 50 °C

6.2: pH 3 / Acidic conditions

With potassium tert-butylate; water; N-methoxylamine hydrochloride; iron; potassium carbonate; triethylamine; HATU; lithium hydroxide; copper diacetate; In tetrahydrofuran; N,N-dimethyl-formamide;

Reference yield:

methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate (1203486-58-1) → 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid (1372540-25-4)

Guidance literature:

Multi-step reaction with 3 steps

1.1: iron / 5 h / Reflux

2.1: potassium carbonate / N,N-dimethyl-formamide / 3 h / 80 °C

3.1: water; lithium hydroxide / tetrahydrofuran / 1 h / 50 °C

3.2: pH 3 / Acidic conditions

With water; iron; potassium carbonate; lithium hydroxide; In tetrahydrofuran; N,N-dimethyl-formamide;

upstream raw materials:

methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate

5-chloro-2-nitrobenzoic acid

3-amino-5-chloro-2-nitrobenzoic acid methyl ester

methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate

Downstream raw materials:

2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide

2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt

ethyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate

C₂₂H₂₁ClF₃N₃O₂

Refernces

• 1、 -. "Combination Drug Therapy". Paragraph 0054; 0055. . Retrieved 2016/10/27.
• 2、 -. "BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS". Page/Page column 35. . Retrieved 2012/04/18.